Lite Strategy (LITS) Stock Price, News & Analysis

Company Overview

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.97 to $1.01
• 50-Day Range: $0.82 to $1.05
• 52-Week Range: $0.69 to $5.15
• Volume: 43,369 shs
• Average Volume: 328,753 shs
• Market Capitalization: $34.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lite Strategy Stock Analysis - MarketRank™

Lite Strategy scored higher than 21% of companies evaluated by MarketBeat, and ranked 777th out of 852 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Lite Strategy has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lite Strategy has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lite Strategy is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lite Strategy is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.47% of the float of Lite Strategy has been sold short.

Short Interest Ratio / Days to Cover

Lite Strategy has a short interest ratio ("days to cover") of 1.48, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lite Strategy has recently increased by 38.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lite Strategy does not currently pay a dividend.

Dividend Growth

Lite Strategy does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Lite Strategy has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.95 average news sentiment score of Finance companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lite Strategy this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $21,500.00 in company stock, which represents 0.0626% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Lite Strategy insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.60% of the stock of Lite Strategy is held by insiders.

Percentage Held by Institutions

52.38% of the stock of Lite Strategy is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 9/01/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance
• Industry: Financial Services
• Sub-Industry: Multi-Sector Holdings
• Current Symbol: NASDAQ:LITS
• CIK: 1262104
• Web: meipharma.com
• Phone: (858) 369-7100
• Fax: 302-655-5049
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -90.81%
• Return on Assets: -89.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.53
• Quick Ratio: 11.53

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,025,000
• Free Float: 33,481,000
• Market Cap: $34.20 million
• Optionable: N/A
• Beta: 0.21